Introduction
============

P-glycoprotein (Pgp) is expressed in the plasma membrane of blast cells in ∼40% patients with acute myeloid leukaemia (AML).^[@bib1]^ Pgp functions as a drug efflux pump that can account for the failure of many drugs to reach their intracellular targets. Such drugs include the common AML-treatment drugs daunorubicin and etoposide. Overexpression of Pgp by AML blasts is well established as a determinant of resistance to remission-induction chemotherapy, and confers inferior disease-free survival and overall survival (OS) in patients receiving conventional anthracycline-containing remission-induction regimens.^[@bib2],\ [@bib3]^

Attempts to improve outcome by including a Pgp-reversal agent in clinical trials have largely been unsuccessful.^[@bib4]^ Some clinical benefit was shown in a study in relapsed patients from the Southwest Oncology Group using cyclosporin as a modulator of daunorubicin given by continuous infusion.^[@bib5]^ This trial showed a superior response rate and OS in relapsed patients in the cyclosporin arm. Cyclosporin also appeared to have some benefit in a non-randomised comparison of previously untreated elderly patients, with an improved complete remission (CR) rate for Pgp-positive patients treated with the modulator.^[@bib6]^ Cyclosporin is thought not to be an ideal choice as a modulator because of its immunosuppressive properties and its potential for nephrotoxicity. The cyclosporin analogue PSC-833 had the potential benefit of less immunosuppression and renal toxicity, but trials of PSC-833 have failed to show benefit.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11]^ The third-generation agent zosuquidar has also failed to show significant benefit in a randomised trial.^[@bib12]^

The FLAG (Fludarabine, Ara-C plus G-CSF) regimen with or without the addition of idarubicin (FLAG-Ida) has featured in several studies as induction therapy for relapsed AML and for patients who failed to achieve remission with standard daunorubicin and Ara-C (DA) regimens,^[@bib13],\ [@bib14]^ and has been a successful strategy in refractory AML with documented Pgp-induced multidrug resistance.^[@bib14]^ The cytotoxicity of FLAG is from the individual toxicities of fludarabine and Ara-C and from the potentiation of Ara-C toxicity by fludarabine and G-CSF. As fludarabine and Ara-C are not Pgp-substrate drugs, this combination may be effective at bypassing Pgp-related resistance mechanisms in primary AML cells. Pgp-related FLAG toxicity has also been studied *in vitro*: using the MRK16 antibody to define Pgp positivity, we found a clear advantage for DA treatment in Pgp-negative AML samples but, in contrast, Pgp-positive AML cells were found to be more responsive to FLAG than to DA.^[@bib15]^ Furthermore AML cells with the highest expression of Pgp had the greatest differential response to FLAG.^[@bib15]^ Furthermore, a group of centres, which had been using FLAG for remission induction in *de novo* AML, published a case--control study of Pgp and induction regimens with and without fludarabine, which suggested that this agent was of benefit in Pgp-positive cases.^[@bib16]^ Idarubicin is also of potential benefit in Pgp-positive AML cases. Although the drug is effluxed by Pgp, its increased lipophilicity and thus enhanced uptake leads to greater toxicity compared with daunorubicin in drug-resistant cells.^[@bib17],\ [@bib18]^ Pgp did not affect clinical responses to idarubicin-containing remission-induction therapy^[@bib19]^ and appeared not to confound response to idarubicin monotherapy in heavily pre-treated patients.^[@bib20]^

One study of FLAG with idarubicin (FLAG-Ida) used as first-line AML-induction therapy produced a CR rate of 82%,^[@bib21]^ confirming the efficacy of this regimen and providing a rationale for comparison with daunorubicin and Ara-C (DA), as FLAG-based regimens had never been compared with DA in a randomised way for remission-induction therapy in *de novo* AML. This was one of the principal questions addressed by the MRC AML15 Trial. This trial therefore represented an opportunity to link a study of the interaction of Pgp with different induction regimens within a large randomised trial of AML therapy. Patients in AML15 were randomised to receive DA, ADE or FLAG-Ida with an additional randomisation to Mylotarg.

Methods
=======

Patients
--------

The AML15 trial was open to all patients with *de novo* or secondary AML aged 15--60 years, and also to patients aged 60 years or over for whom intensive therapy was considered appropriate. Amendments were made to the AML15 protocol during the course of the trial, but samples used in this study were collected before June 2006 which covered a period when the remission-induction randomisations (in non-M3 patients) were to receive one of three induction regimens ADE, DA or FLAG-Ida for the first two courses of treatment with an additional randomisation to Mylotarg (3 mg/m^2^) given on day 1 of course 1. Details, including a cohort diagram, are published elsewhere.^[@bib22]^ Results of the randomisation to Mylotarg are not included in the current analysis; previous work showed no interaction for outcomes of the Mylotarg randomisation with Pgp.^[@bib22]^ Patients not scheduled for transplant were randomised after course 2 to two further courses comprising amsacrine, Ara-C, etoposide (MACE) and mitozantrone and Ara-C (MidAc) or high-dose Ara-C at one of two doses (3 or 1.5 g/m^2^), in a 2:1:1 randomisation, and to receive or not a fifth course of chemotherapy.

Laboratory analysis
-------------------

Presentation of bone marrow or peripheral blood samples (*n*=464) for Pgp analysis were taken into preservative-free heparin or into EDTA tubes and sent to one of two laboratories in Nottingham and Cardiff between 2002 and 2006. Pgp was not measured in patients with M3 AML. Children were also excluded due principally to the large number of tests that needed to be performed on limited material, but also because prognostically significant Pgp overexpression is uncommon in pediatric cases.^[@bib23],\ [@bib24]^ Details of the methodology and of the reproducibility studies undertaken to ensure agreement between the two laboratories are published elsewhere.^[@bib1],\ [@bib25],\ [@bib26]^ Briefly Pgp protein was measured using the MRK16 antibody and function was measured using modulation by PSC-833 of rhodamine 123 retention. Cells were counterstained with CD45 to identify the blast (CD45low/side scatter low) population in flow-cytometric analysis.

Definition of endpoints
-----------------------

The outcome definitions used follow the international guidelines of Cheson *et al.*^[@bib27]^ In the original protocol, patients did not require peripheral count recovery to achieve CR; however, in this report, CR required neutrophil recovery to 1.0 × 10^9^/l and platelets to 100 × 10^9^/l, without evidence of extramedullary disease. Patients who achieved CR according to the protocol, but without recovery are denoted here as CRi. Remission failures were classified by the investigating clinician as due to induction death (death related to treatment and/or hypoplasia within 30 days), or resistant disease (failure to eliminate disease, including partial remissions). Where clinician evaluation was not available, deaths within 30 days were deemed induction death and other failures resistant disease. All percentages are quoted at 5 years.

Statistical analysis
--------------------

Details of the clinical endpoints are as published previously^[@bib22]^ and are in line with IWG Guidelines.^[@bib27]^ Mantel--Haenszel and χ^2^-tests were used to test for differences in demographical and clinical data by Pgp status. Kaplan--Meier curves were constructed for survival data and compared by means of the log-rank test. Multivariate Cox models were used to analyze cumulative incidence of relapse and OS. Multivariate models were adjusted for factors as specified and interactions were tested using the deviance. Surviving patients were censored at 1 January 2009, with follow-up complete for 97% of patients. Hazard ratios and 95% confidence intervals are quoted for endpoints. In all cases a ratio of \<1 indicates benefit for higher Pgp levels. All *P*-values are two-tailed.

Results
=======

Demographics and laboratory correlates
--------------------------------------

Demographic data are displayed in [Table 1](#tbl1){ref-type="table"}. Patients were primarily under 60, although 13% of the cohort studied for Pgp was older. Of the 464 samples processed, there were sufficient viable cells to measure protein and/or function in 434 and both in 348. Pgp protein was measured in 368 samples and Pgp function in 412. in all, 34% of cases were positive for Pgp protein and 38% for function (23% low and 15% high). The median age of this cohort was 48. [Table 1](#tbl1){ref-type="table"} incorporates an examination of factors previously indicated to be associated with Pgp expression, such as age, white cell count, cytogenetics and secondary AML.^[@bib1],\ [@bib28]^ In this relatively young cohort, with less secondary AML or adverse cytogenetics than in the elderly, Pgp positivity remained associated with age (*P*=0.01) and with a lower white count (*P*=0.002) ([Table 1](#tbl1){ref-type="table"}). Comparison with contemporaneous adult trial patients with non-APL AML not included in this data set (*n*=1166), demonstrated that there were no significant differences in age, sex, performance status or cytogenetic group between patients with data on Pgp and those without, although patients in this study were slightly less likely to have secondary disease (6% vs 9%, *P*=0.05) and had slightly higher white blood cell count (median 13.2% vs 9.7, *P*=0.02) than those in the rest of AML15. Outcomes, however, were similar between groups.

Effect of Pgp on outcome in the entire cohort
---------------------------------------------

Overall, Pgp was associated with an inferior CR rate in unadjusted analysis---odds ratio (OR) 1.91 (1.03--3.55) *P*=0.04, [Table 2](#tbl2){ref-type="table"}, but did not significantly affect the CR rate after adjustment for age, WBC, sex, secondary disease, performance status and cytogenetics (standard co-variates in MRC AML Trial analysis).^[@bib22]^ As Pgp might be expected to affect the cellular response to chemotherapy, but not to have an effect on induction deaths, we also studied primary resistant disease. Pgp protein-positive cases had a higher incidence of primary resistant disease (14% vs 5%), adjusted OR 2.67 (1.14--6.24) *P*=0.02, [Table 2](#tbl2){ref-type="table"}.

There was a trend towards a lower cumulative incidence of relapse at 5 years for Pgp-negative cases (46% vs 55%, adjusted hazard ratio 1.42; 0.98--2.07, *P*=0.06), but this did not translate into a significant survival benefit ([Table 2](#tbl2){ref-type="table"}). Results for Pgp function were similar, although the association with primary resistant disease was lost in the adjusted data set, whereas a marked association was noted between Pgp function and poor relapse-free survival ([Table 3](#tbl3){ref-type="table"} and [Figure 1](#fig1){ref-type="fig"}).

Impact of induction regimen on treatment outcome in Pgp-positive and -negative AML
----------------------------------------------------------------------------------

The impact of individual induction regimens on initial response is shown in [Table 4](#tbl4){ref-type="table"}. For patients receiving DA/ADE-induction therapy the CR rate was lower in Pgp+AML compared with Pgp-negative cases (78% compared with 90%, OR 2.74 (1.27--5.89) *P*=0.01). In contrast the CR rate for FLAG-Ida was 86% for both Pgp-positive and -negative patients (OR 0.97 (0.34--2.78) *P*=1.0). The adjusted *P*-value for the interaction between Pgp and induction treatment for CR rate was 0.06.

For patients receiving ADE/DA, the incidence of primary resistant disease was 6% in the Pgp-negative cohort and 18% in Pgp-positive cases, OR 3.84 (1.55--9.53), *P*=0.004, whereas no significant difference was observed between Pgp-positive and -negative cases treated with FLAG/Ida. The *P*-value for interaction was 0.8, but with such a low incidence of primary resistant disease in the trial, this comparison was underpowered for statistical analysis. There were no significant interactions association between Pgp function and CR rate.

We have reported that for all patients entered into the AML15 trial the cumulative incidence of relapse was lower for patients given FLAG-Ida compared with ADE.^[@bib29]^ However, the cumulative incidence of relapse rate for Pgp-positive patients in both arms was greater than for Pgp-negative patients: the adjusted *P*-value for the interaction with protein was 0.07, and *P*=0.4 for function ([Figure 2](#fig2){ref-type="fig"}).

There was no significant interaction between Pgp protein or function and treatment group affecting OS ([Figure 3](#fig3){ref-type="fig"}): the adjusted *P*-values for the interaction were 0.4 for protein and 0.8 for function.

Discussion
==========

A previous study of the interaction between Pgp and regimens with or without fludarabine (comprising fludarabine, AraC, idarubicin±etoposide) adopted an age-matched case--control strategy and found an improved CR rate, OS and disease-free survival for Pgp-positive patients with regimens containing fludarabine.^[@bib16]^ In the randomised AML15 trial, results on CR are in agreement with this and show a CR/CRi rate of 86% for Pgp-positive patients with FLAG-Ida, which was the same as that seen in Pgp-negative AML. In contrast, patients receiving induction regimens incorporating the Pgp substrates daunorubicin and etoposide (DA/ADE) had a lower CR rate if they were Pgp+. This is the second randomised controlled trial in *de novo* AML to have shown a benefit for an intervention in the Pgp+ group. Previously, quinine was also shown to improve the CR rate but not OS in Pgp+ AML patients.^[@bib30]^ Other strategies attempted, particularly the use of Pgp inhibition with PSC833 or zosuquidar, have failed to improve outcomes in this group of patients.^[@bib7],\ [@bib8],\ [@bib9],\ [@bib10],\ [@bib11],\ [@bib12]^

Regarding relapse, results for AML15 previously reported showed that FLAG-Ida resulted in a reduced relapse rate overall compared with DA/ADE.^[@bib29]^ Both Pgp-positive and -negative patients benefited in this respect from FLAG-Ida treatment, but in contrast to the case--control study, we found a significant interaction between Pgp and treatment received with respect to relapse rate, with Pgp-positive patients having a higher relapse rate than Pgp-negative patients in both treatment arms. Furthermore there was no interaction between Pgp and treatment received in effect on OS. Thus the use of FLAG-Ida induction in Pgp-positive cases induces a slight shift in initial efficacy, such that efficient clonal reduction results in improved CR for this subgroup, but these patients have an increased frequency of relapse with a consequent lack of effect on OS. These data suggest that in the most chemoresistant samples, the leukaemic clone is reduced rather than eradicated, such that relapse is high in these cases. Pgp is not necessarily overexpressed in all leukaemic stem and progenitor cells. However, we have previously determined that Pgp expression in the CD34+CD38 subset, which contains the leukaemia initiating cells, correlates strongly with expression in the sample as a whole, suggesting that when a sample is Pgp positive, relapse is likely to be driven by Pgp-positive cells within this sub-population.^[@bib31]^ However, factors driving chemoresistance in the MRD cells of Pgp-negative samples remain to be determined. The suggestion that Pgp is acquired during the course of remission-induction chemotherapy is a possibility, but remains unproven.^[@bib11],\ [@bib32],\ [@bib33]^ We investigated an alternative explanation for the altered CR and relapse rates in Pgp+ patients treated with fludarabine-based regimens, namely that post-remission regimens, including use of stem cell transplants, may have differed. Consolidation regimens were randomised in the AML15 trial, although uptake in the FLAG-Ida arm of the trial was lower than in the ADE/DA part of the trial. Overall within AML15, as was demonstrated in the initial report of the results,^[@bib29]^ significantly improved relapse-free survival was obtained with FLAG-Ida compared with daunorubicin-containing regimens. In the study reported here, rates of allogeneic transplantation were similar between groups (ADE/DA 20%, FLAG-Ida 15%, *P*=0.2). We therefore consider it unlikely that the results seen arise out of differences in post-remission treatment, although numbers are too small to rule this out with absolute certainty.

Slight distinctions between Pgp protein and function have been noted in this study and we have commented on this previously.^[@bib1]^ We used PSC-833 in our functional assay and although this is more specific than other modulators in the literature, it has not been studied in genetic models of all 49 ABC transporters, and other efflux pumps may be affected in this assay. The major impact of functionally defined Pgp in our study was on relapse, so the possibility that the leukaemic stem cells that drive relapse have additional pumps affected in the functional assay is logical but completely speculative.

Our study shows a high CR/CRi rate in AML15 Pgp-positive patients compared with other studies reported in the literature. [Table 5](#tbl5){ref-type="table"} represents a compilation of remission data, from studies in which the Pgp status of patients is known. Some studies comprised a wide range of patient ages, so we have selected those with a median age \<60 to afford a reasonable comparison with our data. All patients were treated with chemotherapy containing ara-C and an anthracycline. The CR/CRi rate for Pgp-positive adult patients in AML15 receiving FLAG-Ida was over 10% higher than that reported in these historical controls.

Only one report of those listed in [Table 5](#tbl5){ref-type="table"} failed to show a difference in CR rate between Pgp-positive and -negative patients: this study is notable in that idarubicin was used in preference to daunorubicin, and fludarabine was not included in the treatment protocol.^[@bib19]^ This serves as a reminder that the effects we have observed in the current study maybe a result of the interaction between fludarabine and idarubicin or to either of these drugs individually. Prospective analysis of Pgp in clinical specimens has been hampered by a literature in the 1990s showing that Pgp is difficult to measure. More recently, however, multi-centre analysis of AML samples has shown that reliable, quick measurements of Pgp function are feasible.^[@bib1],\ [@bib26]^ We hope that other groups using fludarabine and idarubicin will consider measuring Pgp in their patients.

In conclusion our data indicate that FLAG-Ida may improve the remission rate for Pgp-positive AML, but the malignant clone is reduced rather than eradicated such that the relapse rate remains high in Pgp-positive patients, irrespective of remission-induction therapy. However the high CR rate obtained with FLAG-Ida in Pgp-positive AML may permit more patients to progress to allogeneic transplantation in first CR.
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![Relpase risk stratified by treatment, Pgp protein and Pgp function. (**a**) Pgp protein, DA/ADE; (**b**) Pgp function, DA/ADE; (**c**) Pgp protein, FLAG-Ida; and (**d**) Pgp function, FLAG-Ida.](bcj201123f2){#fig2}

![OS stratified by treatment, Pgp protein and Pgp function. (**a**) Pgp protein, DA/ADE; (**b**) Pgp function, DA/ADE; (**c**) Pgp protein, FLAG-Ida; and (**d**) Pgp function, FLAG-Ida.](bcj201123f3){#fig3}

###### Demographic data

                         *Pgp protein (number)*             *Pgp function (number)*                                                        
  ---------------------- ---------------------------------- ------------------------- --- ----- ------------------------------------- ---- ---
  *Age*                  0.01[a](#t1-fn1){ref-type="fn"}                                        0.05[a](#t1-fn1){ref-type="fn"}            
   \<15                  0                                  0                             1     0                                     0     
   15--29                42                                 19                            32    25                                    4     
   30--39                42                                 13                            43    7                                     6     
   40--49                56                                 23                            57    24                                    14    
   50--59                83                                 44                            95    27                                    23    
   60--69                21                                 25                            26    12                                    16    
   70+                   0                                  0                             0     0                                     0     
                                                                                                                                            
  *Sex*                  0.03                                                                   0.07[a](#t1-fn1){ref-type="fn"}            
   Female                126                                49                            129   44                                    24    
   Male                  118                                75                            125   51                                    39    
                                                                                                                                            
  *Performance status*   0.18[a](#t1-fn1){ref-type="fn"}                                        0.11[a](#t1-fn1){ref-type="fn"}            
   0                     156                                88                            154   69                                    42    
   1                     78                                 33                            87    22                                    20    
   2                     6                                  1                             6     1                                     1     
   3                     3                                  2                             5     3                                     0     
   4                     1                                  0                             1     0                                     0     
                                                                                                                                            
  *Secondary disease*    0.6                                                                    0.2[a](#t1-fn1){ref-type="fn"}             
   No                    233                                120                           246   91                                    59    
   Yes                   11                                 4                             8     4                                     4     
                                                                                                                                            
  *WBC*                  0.002[a](#t1-fn1){ref-type="fn"}                                       \<0.0001[a](#t1-fn1){ref-type="fn"}        
   \<10                  71                                 57                            69    48                                    42    
   10--49.9              92                                 40                            98    31                                    12    
   50--99.9              43                                 18                            47    10                                    7     
   100+                  36                                 9                             38    6                                     2     
   Unknown               2                                  0                             2     0                                     0     
                                                                                                                                            
  *Cytogenetics*         0.4[a](#t1-fn1){ref-type="fn"}                                         0.08[a](#t1-fn1){ref-type="fn"}            
   Favourable            35                                 20                            29    26                                    4     
   Intermediate          155                                65                            166   42                                    33    
   Adverse               17                                 17                            15    12                                    12    
   Unknown               37                                 22                            44    15                                    14    

Mantel--Haenszel test for trend: all others test for heterogeneity.

###### Responses of the entire cohort (*n*=348) according to Pgp protein status

                      *Protein negative (%)*   *Protein positive (%)*   *Unadjusted OR/HR, 95% CI;* P*-value*   *Adjusted OR/HR, 95% CI;* P*-value*
  ------------------- ------------------------ ------------------------ --------------------------------------- -------------------------------------
  CR/CRi              89                       81                       1.91 (1.03--3.55); 0.04                 1.51 (0.78--2.92); 0.2
  Resistant disease   5                        14                       3.35 (1.50--7.46); 0.003                2.67 (1.14--6.24); 0.02
  5-year OS           46                       33                       1.27 (0.95--1.71); 0.10                 1.13 (0.82--1.55); 0.5
  5-year RFS          45                       32                       1.32 (0.97--1.01); 0.08                 1.34 (0.95--1.88); 0.09
  5-year CIR          46                       55                       1.33 (0.94--1.88); 0.11                 1.42 (0.98--2.07); 0.06

Abbreviations: CI, confidence interval; CIR, cumulative incidence of relapse; CR, complete remission; HR, hazard ratio; OR, odds ratio; OS, overall survival; Pgp, p-glycoprotein; RFS, relapse-free survival.

###### Responses of the entire cohort (*n*=412) according to Pgp function status

                      *Function negative (%)*   *Function low (%)*   *Function high (%)*   *Unadjusted OR/HR, 95% CI;* P*-value*   *Adjusted OR/HR, 95% CI;* P*-value*
  ------------------- ------------------------- -------------------- --------------------- --------------------------------------- -------------------------------------
  CR/CRi              87                        87                   78                    1.30 (0.92--1.84); 0.14                 1.13 (0.75--1.70); 0.6
  Resistant disease   6                         6                    17                    1.78 (1.16--2.76); 0.009                1.45 (0.88--2.40); 0.14
  5-year OS           46                        42                   28                    1.17 (0.99--1.39); 0.06                 1.12 (0.93--1.36); 0.3
  5-year RFS          46                        34                   24                    1.26 (1.06--1.51); 0.01                 1.26 (1.03--1.54); 0.02
  5-year CIR          47                        52                   63                    1.24 (1.02--1.51); 0.03                 1.27 (1.02--1.59); 0.03

Abbreviations: CI, confidence interval; CIR, cumulative incidence of relapse; CR, complete remission; HR, hazard ratio; OR, odds ratio; OS, overall survival; Pgp, p-glycoprotein; RFS, relapse-free survival.

###### Response rates stratified by treatment arm

                                     *ADE/DA*            *FLAG*               P*-value for interaction*
  ---------------------------------- ------------------- -------------------- ---------------------------
  *CR/CRi*                                                                    
   Protein negative (%)              90 (142/158)        86 (74/86)           Unadjusted: 0.1
   Protein positive (%)              78 (62/80)          86 (38/44)           Adjusted: 0.06
   OR and 95% CI                     2.74 (1.27--5.89)   0.97 (0.34--2.78)     
   Unadjusted *P*-value (protein)    *P*=0.01            *P*=1.0               
   Function negative (%)             87 (141/163)        87 (78/90)           Unadjusted: 0.2
   Low function (%)                  89 (57/64)          84 (26/31)           Adjusted: 0.15
   High function (%)                 71 (30/42)          90 (19/21)            
   OR and 95% CI (per level)         1.49 (0.99--2.26)   0.92 (0.47--1.79)     
   Unadjusted *P*-value (function)   *P*=0.06            *P*=0.8               
                                                                               
  *Resistant disease*                                                         
   Protein negative (%)              6 (9/158)           3 (3/86)             Unadjusted: 0.5
   Protein positive (%)              18 (14/80)          7 (3/44)             Adjusted: 0.8
   OR and 95% CI                     3.84 (1.55--9.53)   2.12 (0.38--11.89)    
   Unadjusted *P*-value (protein)    *P*=0.004           *P*=0.4               
   Function negative (%)             8 (13/163)          2 (2/90)             Unadjusted: 0.8
   Low function (%)                  6 (4/64)            6 (2/31)             Adjusted: 0.9
   High function (%)                 24 (10/42)          5 (1/21)              
   OR and 95% CI per level           1.81 (1.12--2.94)   1.60 (0.55--4.68)     
   Unadjusted *P*-value (function)   *P*=0.02            *P*=0.4               

Abbreviations: CI, confidence interval; CR, complete remission; OR, odds ratio.

###### CR/CRi rates for Pgp-positive and -negative previously untreated patients with a median age \<60 (listed in order of increasing median age)

  *Reference*                                *CR rate*               *Median age*        
  ---------------------------------- ------------------------- ------------------------- --------
  Solary^[@bib30]^                            67 (CR)                   82 (CR)          41
  Broxterman^[@bib19]^                      68 (CR+CRi)               71 (CR+CRi)        43
  Leith^[@bib34]^                             48 (CR)                   54 (CR)          44
                                                                                          
  ***This study---overall***          **81 (CR+CRi) (76 CR)**   **89 (CR+CRi) (85 CR)**  **48**
   **ADE/DA**                         **78 (CR+CRi) (71 CR)**   **90 (CR+CRi) (85 CR)**   
   **FLAG-Ida**                       **86 (CR+CRi) (84 CR)**   **86 (CR+CRi) (85 CR)**   
                                                                                          
  Van den Heuvel-Eibrink^[@bib35]^            36 (CR)                   77 (CR)          51
  Damiani^[@bib36]^                           56 (CR)                   85 (CR)          53
  Marzac^[@bib37]^                            41 (CR)                   67 (CR)          54
  Schaich^[@bib38]^                           31 (CR)                   56 (CR)          56
  Del Poeta^[@bib39]^                         40 (CR)                   72 (CR)          57

Abbreviations: CR, complete remission; Pgp, p-glycoprotein.
